Hua Medicine Company

Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Technology:
Small Molecules
Industry:
PharmTech
Headquarters:
Shanghai, Shanghai, China
Zip:
101-250
Founded Date:
2010-01-01
Employees Number:
101-250
Funding Status:
IPO
Acquisitions Number:
20
Investors Number:
242400000
Total Funding:
Less than $1M
Estimated Revenue:
2018-09-13
Last Funding Date:
Series E
Last Funding Type:
BD@huamedicine.com
Register and Claim Ownership